Devimistat | CPI-613 | CAS#95809-78-2 | Antineoplastic | MedKoo Biosciences
Cornerstone Pharmaceuticals Lead Compound CPI-613
An integrated in vivo and in silico analysis of the metabolism disrupting effects of CPI-613 on embryo-larval zebrafish (Danio rerio) - ScienceDirect
Devimistat (CPI-613) (Devimistat) | CAS 95809-78-2 | AbMole BioScience | Devimistat (CPI-613) Price
Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study | Future Oncology
Rafael Holdings, Inc. 2021 Current Report 8-K
Cancers | Free Full-Text | The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
Mitochondria in cancer metabolism, an organelle whose time has come? - Abstract - Europe PMC
Devimistat - Wikipedia
ラファエルホールディングスの適時開示・その他 | 米国株｜株探（かぶたん) - 株探
Devimistat (CPI-613) | デヒドロゲナーゼ 阻害剤
CPI-613 | CAS:95809-78-2 | PDH/α-KGDH inhibitor | High Purity | Manufacturer BioCrick
CPI-613 | CAS:95809-78-2 | PDH/α-KGDH inhibitor | High Purity | Manufacturer BioCrick
A combination of CPI-613 and chloroquine significantly suppressed tumor... | Download Scientific Diagram
Prolongation of survival induced by four doses of CPI-613 (25 mg/kg),... | Download Scientific Diagram
The Mitochondrion as an Emerging Therapeutic Target in Cancer: Trends in Molecular Medicine
Cancers | Free Full-Text | The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
The Pyruvate Dehydrogenase Complex in Cancer: Implications for the Transformed State and Cancer Chemotherapy | IntechOpen
